The benefits of valsartan in the treatment of heart failure: Results from Val-HeFT

International Journal of Clinical Practice

Volumn 58, Issue 2, 2004, Pages 184-191

  Tan, L B ^a   Schlosshan, D ^a   Williams, S G ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitor; Angiotensin receptor blockers; Heart failure; Treatment; Valsartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; NORADRENALIN; PLACEBO; VALSARTAN;

ADULT; AGED; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR REMODELING;

EID: 1842486160     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.0134.x     Document Type: Review

References (40)

1. Sanderson JE, Tse T-F. Heart failure: A global disease requiring a global response. Heart 2003; 89: 585-6.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of caGdiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-53.
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of carViovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-64.
4. Basile J, Johnson RH. New strategies for improving heart failure management: A primary care perspective. South Med J 2001; 94: 166-74.
5. Cowie MR, Zaphiriou A. Management of chronic heart failure. BMJ 2002; 325: 422-5.
6. Abraham WT, Scarpinato L. Higher expectations for management of heart failure: Current recommendations. J Am Board Fam Pract 2002; 15: 39-49.
7. American Heart Association. 2002 Heart and Stroke Statistical Update Dallas, Texas: American Heart Association, 2001.
8. Levy D, Larson MG, Vasan RS et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1604-6.
9. Burnier M, Brunner HR. Angiontensin II receptor antagonists. Lancet 2000; 355: 637-45.
10. Benjamin IJ, Jalil JE, Tan LB et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65: 657-70.
11. Tan LB, Jalil JE, Pick R et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-95.
12. Ng Y, Goldspink DF, Clark WA et al. Isoprenaline induces myocyte necrosis in rat skeletal muscle: Comparison with effects on cardiomyocytes. Int J Cardiol 2002; 86: 299-309.
13. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
14. ACC/AHA Task Force. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. American College of Cardiology and the American Heart Association, Inc., 2001. J Am Coll Cardiol 2001; 38: 2101-13.
15. McMurray J, Neuhart E, Held P et al. Clinical trials with angiotensin II receptor antagonists in heart failure and myocardial infarction. Br J Cardiol 1999; 6: 566-76.
16. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42.
17. Maggioni AP, Latini R. The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in ten years? Blood Press 2002; 11: 328-38.
18. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
19. Cohn JN, Tognoni G, Glazer R et al. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, and angiotensin-receptor-blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155-60.
20. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: Results from Val-HeFT. J Card Fail 2003; 9: 164-71.
21. Wong M, Chiang Y, Glazer R, Cohn JN, for the Val-HeFT Investigators. Signs and symptoms of heart failure as endpoints for assessing therapeutic response: Val-HeFT data. Eur Heart J 2003; 24 (Suppl.): 146 (Abstract 856).
22. Majani G, Giardini A, Opasich C et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: Results from the Valsartan Heart Failure Trial. Cardiovasc Drugs Ther (submitted for publication).
23. Tavazzi L, Pina I, Chiang Y et al. Association of quality of life with improved clinical outcomes: Results from the Valsartan Heart Failure Trial. J Am Coll Cardiol 2002; 39 (Suppl. A): 1134-55 (Abstract).
24. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970-5.
25. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-8.
26. Cohn JN, Anand IS, Latini R et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Circulation 2003; 108: 1306-9.
27. Cha AJ, Malecha SE, Judge KW. Aldosterone, a new appreciation of its role in heart failure. Pharmacotherapy 2000; 20: 1107-15.
28. Majahalme S. Demographics, treatment regimens and the use of angiotensin receptor blockers in heart failure. J Int Med Res 2003; 31: 351-61.
29. Majahalme SK, Baruch L, Aknay N et al. Mortality and morbidity in men, women and postmenopausal women in Val-HeFT. J Am Coll Cardiol 2003; 41 (Suppl. 1): 205.
30. Holwerda NJ, Opie L, Feliciano N et al. Effect of valsartan on morbidity and mortality in heart failure patients with a history of hypertension: Results from the Valsartan Heart Failure Trial. J Am Coll Cardiol 2002; 39 (Suppl. 1): 249.
31. Maggioni AP, Anand I, Gottlieb SO et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414-21.
32. Marentette MA, Gerth WC, Billings DK et al. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18: 649-56.
33. Degli Esposti E, Sturani A, Di Martino M et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-44.
34. Reed SD, Friedman J, Velazquez EJ et al. Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline. Eur Heart J 2002; 23 (Abstract Suppl.): 809.
35. Lechat P. Heart failure treatment: Recommendations versus reality. Eur J Heart Fail (submitted for publication).
36. Bart BA, Gattis WA, Diem SJ et al. Reasons for the underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997; 79: 1118-20.
37. Bungard TJ, McAlister FA, Johnson JA et al. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs 2001; 61: 2021-33.
38. Bart BA, Ertl G, Held P et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20: 1182-90.
39. Johansson S, Wallander MA, Ruigomez A et al. Treatment patterns among newly diagnosed heart failure patients in general practice. Eur J Clin Pharmacol 2002; 57: 813-7.
40. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001; 58: 671-83.